The European Union Committee for Proprietary Medicinal Products has recommended the approval of Hoffmann-La Roche's Roferon-A (interferon alfa-2a) for the treatment of chronic hepatitis C.
In Phase III trials in more than 1,800 patients, the company reported that up to 89% of patients respond to treatment. Response occurs within three months, and a permanent and sustained response, once treatment has been discontinued, can be expected in up to 44% of patients.
The product was first launched in 1986 and is now approved in more than 70 countries for the treatment of different cancers as well as for chronic hepatitis B. In France, Italy and Japan the product is already available for the treatment of chronic hepatitis C.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze